English
简体中文
繁體中文
English
Filipino
हिन्दी
Hmong
Bahasa Indonesia
日本語
Basa Jawa
한국어
ພາສາລາວ
Bahasa Melayu
മലയാളം
ဗမာစာ
سنڌي
தமிழ்
ไทย
Tiếng Việt
Afrikaans
Shqip
العربية
አማርኛ
Հայերեն
Azərbaycan dili
Euskara
Беларуская мова
বাংলা
Bosanski
Български
Català
Cebuano
Chichewa
Corsu
Italiano
Hrvatski
Čeština
Dansk
Nederlands
Esperanto
Eesti
Suomi
Frysk
Galego
ქართული
Ελληνικά
ગુજરાતી
Kreyol ayisyen
Deutsch
Français
Harshen Hausa
Ōlelo Hawaiʻi
עִבְרִית
Magyar
Íslenska
Igbo
Gaeilge
ಕನ್ನಡ
Қазақ тілі
ភាសាខ្មែរ
كوردی
Кыргызча
Latin
Latviešu valoda
Lietuvių kalba
Lëtzebuergesch
Македонски јазик
Malagasy
Maltese
Te Reo Māori
मराठी
Монгол
नेपाली
Norsk bokmål
پښتو
فارسی
Polski
Português
ਪੰਜਾਬੀ
Română
Русский
Samoan
Gàidhlig
Српски језик
Sesotho
Shona
සිංහල
Slovenčina
Slovenščina
Afsoomaali
Español
Basa Sunda
Kiswahili
Svenska
Тоҷикӣ
తెలుగు
Türkçe
Українська
اردو
O‘zbekcha
Cymraeg
isiXhosa
יידיש
Yorùbá
ZuluUSA: A recent study utilizing real-world data from the US Food and Drug Administration (FDA) has revealed a potential link between the use of obesity medications and a decreased risk of developing multiple sclerosis (MS).
Published in the journal Therapeutic Advances in Neurological Disorders, the research focused on medications, including those for diabetes and weight loss, to explore their impact on MS risk.
Protective Effects of GLP-1 Receptor Activation
The study highlighted medications that activate the GLP-1 receptor, known for lowering blood glucose levels, as particularly effective in reducing MS risk. The researchers found that drugs such as semaglutide and dulaglutide, which are used for both diabetes management and weight loss, showed significant protective effects against MS.
Click to Visit website of India's Leading Manufacturer of World Class Dental Materials, Exported to 90+ Countries.
According to the researchers, “Drug repurposing, defined as researching new indications for already approved drugs, is gaining attention as a rapid and cost-efficient strategy for developing new treatments.” They emphasized the potential of anti-diabetic drugs with weight loss-inducing effects, especially GLP-1 receptor agonists, for repurposing opportunities in MS treatment.
Among the medications analyzed, semaglutide was found to reduce the likelihood of developing MS by 76.2%, while dulaglutide reduced it by 83.5%. These findings suggest a promising avenue for further exploration into the use of these medications in MS prevention and treatment.
Mouth Cancer-Detecting Lollipops in Development
In a separate development, researchers at the University of Birmingham have secured funding for a pioneering project aimed at creating mouth cancer-detecting lollipops. These innovative lollipops could revolutionize cancer diagnosis by speeding up detection and identifying cancer at an earlier stage.
The lollipops will be made using a smart material called hydrogel, designed to capture proteins from a patient’s saliva. This hydrogel technology allows for the concentration and labeling of proteins using a fluorescent marker, which can then be observed for any cancer-related biomarkers.
The information and viewpoints presented in the above news piece or article do not necessarily reflect the official stance or policy of Dental Resource Asia or the DRA Journal. While we strive to ensure the accuracy of our content, Dental Resource Asia (DRA) or DRA Journal cannot guarantee the constant correctness, comprehensiveness, or timeliness of all the information contained within this website or journal.
Please be aware that all product details, product specifications, and data on this website or journal may be modified without prior notice in order to enhance reliability, functionality, design, or for other reasons.
The content contributed by our bloggers or authors represents their personal opinions and is not intended to defame or discredit any religion, ethnic group, club, organisation, company, individual, or any entity or individual.